The Company announced its fourth quarter and full year 2017 financial results.
The Company plans on attending the Cowen Health Care Conference on Wednesday, March 14 at 10:40 a.m. ET in Boston and the Barclays Global Healthcare Conference on Thursday, March 15 in Miami.
The Company announced that AT-004, the company’s canine-specific monoclonal antibody targeting CD20 as an aid in the treatment of B-cell lymphoma in dogs, has received a full license from the U.S. Department of Agriculture (USDA).
The Company announced positive results from its pivotal field study of AT-001 (Grapiprant), the company’s innovative drug for treating pain in dogs with osteoarthritis.
Aratana is pleased to announce positive results from its pivotal field study of the company’s innovative drug for treating pain in dogs with osteoarthritis.
Aratana has initiated a pivotal field effectiveness study for an innovative drug for treating post-surgical pain in dogs licensed from Pacira Pharmaceuticals, Inc.
The Company announced the initiation of the pivotal field effectiveness study for AT-003, the company’s innovative drug for treating post-surgical pain in dogs licensed from Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX).
The Company announced that it will present at the 2014 Animal & Dental Health Summit, to be held December 11-12, 2014, at the Bank of America Merrill Lynch Conference Center in Boston.
The Company announced that it will present at the 26th Annual Piper Jaffray Healthcare Conference, to be held December 2-3, 2014, at the New York Palace Hotel in New York.
At Aratana, we are focused on delivering solutions for unmet and underserved medical needs in pets. Over the past few months, we’ve achieved a number of highlights in our diversified portfolio.
The Company announced its third quarter 2014 results and plans to host a conference call November 11, 2014 at 8:30 a.m. ET.
One of the core values of Aratana Therapeutics is our responsibility to improve the lives of our pets. It’s reflected through our dedication to developing new therapeutics for the unmet medical needs of pets and the families who love them.
The Company will host a conference call and live audio webcast on Tuesday, November 11, 2014, at 8:30 a.m. ET, to discuss its financial results for the quarter ended September 30, 2014.
The Company announced the completion of a global licensing agreement for the development and commercialization of a novel oral CRTH2 antagonist for animal health indications.
The Company announced its first appearance at the Annual Veterinary Cancer Society meeting and plans to present data on monoclonal antibody oncology products in a series of presentations and a poster during the meeting.
The Company announced the full exercise of the underwriters’ option to purchase 675,000 additional shares of common stock in connection with the company’s previously announced public offering of 4,500,000 shares of common stock.
The Company announced the pricing of its public offering of 4,500,000 shares of its common stock at a price to the public of $9.25 per share.
The Company announced that it is commencing an underwritten registered public offering of shares of its common stock.